Skip to content Skip to sidebar Skip to footer
Fortescue Future Industries
Fortescue Future Industries: Are the iron giant’s bold green ambitions on track?
In 2020, Fortescue Future Industries was born to realise the then-Twiggy Forrest operated iron ore miner's green ambitions, including in hydrogen. It is no longer a standalone brand and is integrated along with Fortescue's broader operations. The question this article looks at is simple: Is Fortescue walking the talk? What are the Best ASX stocks to invest in…
ASX company spin
ASX Company Spin: Here are 7 occasions when management tries to sell bad news as good news
In all our years, we have seen our fair share of ASX Company Spin. It is repeated because often investors fall for it. Even if not all do, it is sufficient that some investors fall for it to achieve what has to be achieved. For instance, that enough believe a capital raising at a >25% discount…
Cisco Systems
Cisco Systems (NDQ:CSCO): Will this US$300bn company really be a winner from the AI boom? Investors aren’t so sure
As a big company in the networking equipment space, Cisco Systems (NDQ:CSCO) is a company you could be forgiven for thinking will be a winner from AI just by being there. But investor reaction to its latest results suggest investors are currently skeptical. What are the Best ASX stocks to invest in right now? Check our buy/sell…
why share prices fall after a capital raising
If you wondered why share prices fall after a capital raising, Botanix is the ‘perfect’ poster child
We thought this was a perfect time to ponder the question,' Why share prices fall after a capital raising', in light of what happened with Botanix Pharmaceuticals (ASX:BOT). Its shares fell 33% in less than an hour of trading. Now, shouldn't investors be happy that the company has $45m more cash? Let's just say that…
genetype
Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!
Investors may remember Rhythm Biosciences (ASX:RHY) for its ColoSTAT test, but it is Genetype that is arguably more exciting. The company now has a substantially larger market awaiting us, and while its commercialisation strategy for ColoSTAT has changed, this strategy has been successful. Wait, has Rhythm received TGA approval? Yes and no - it's a long…
GPT Group
GPT Group (ASX:GPT): Still hasn’t surpassed pre-COVID levels, but is it finally out of the doldrums now?
GPT Group (ASX:GPT) released its annual results (for CY25) yesterday, but the market reaction was nuanced and it remains below pre-COVID levels. Is this company just an undeserved victim of the levels of investor appetite for REITs, or is there something at the fundamental level warranting it to have not reached levels last reached 6…
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here